Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
RCMT provides advisory and regulatory-support services via its Life Sciences & IT offerings, aligning with Laboratory Testing & Advisory Services.
|
$170.79M |
$23.11
-3.10%
|
|
Emrosi is an oral small molecule therapeutic for rosacea, representing Journey Medical's core product avenue.
|
$169.83M |
$7.29
+0.41%
|
|
Insighta FRAGMA liquid biopsy enables multi-cancer early detection, a key diagnostic technology.
|
$169.77M |
$13.89
-3.94%
|
|
Company is a biotech focused on oncology immunotherapies leveraging a platform (AMP) for cancer treatment.
|
$169.25M |
$10.58
-5.11%
|
|
Acquisition adds gene editing assessment services and lab testing/advisory offerings.
|
$167.98M |
$1.66
+5.06%
|
|
Growth Direct functions as a diagnostic instrument for microbial detection in QC workflows.
|
$167.56M |
$3.79
+7.37%
|
|
Direct product: DurAVR Transcatheter Heart Valve (TAVR) system in the structural heart/cardiology devices category.
|
$166.25M |
$4.61
-6.11%
|
|
CGEN's core business is immuno-oncology, developing antibody-based therapies (e.g., COM701) and advancing IO assets.
|
$165.64M |
$1.85
-5.13%
|
|
Company directly manufactures ophthalmology devices (OMNI/OMNIEdge, TearCare, SION Surgical Instrument) used in interventional eye care.
|
$165.45M |
$3.20
-5.04%
|
|
Innate Pharma's core pipeline is oncology-focused, including monoclonal antibodies and antibody-based immunotherapies (lacutamab and monalizumab).
|
$164.36M |
$2.03
+2.53%
|
|
TriNav infusion system is a medical device used in embolization procedures, which aligns with Surgical Equipment.
|
$163.46M |
$4.32
-2.26%
|
|
CytoDyn's leronlimab is a CCR5-targeting biologic being developed for oncology, fitting Biotech - Oncology.
|
$163.45M |
$0.27
+2.97%
|
|
Medical Imaging reflects CT imaging hardware produced via Healthcare asset stream (CT tubes, imaging equipment).
|
$163.04M |
$11.25
-2.43%
|
|
Company's core platform is gene therapy using zinc finger and ZFR technologies, a direct gene therapy product category.
|
$156.76M |
$0.67
-10.35%
|
|
Ionis partnership (donidalorsen and olezarsen) targets rare diseases in Canada with meaningful profitability potential.
|
$155.87M |
$3.39
+0.89%
|
|
TNX-102 SL is a non-opioid, small-molecule therapeutic formulated as a sublingual tablet for fibromyalgia.
|
$155.21M |
$21.19
-4.46%
|
|
PepGen's core differentiator is the Enhanced Delivery Oligonucleotide (EDO) platform, a drug-delivery platform for oligonucleotide therapies.
|
$154.28M |
$4.71
-3.78%
|
|
Lead pipeline SER-155/SER-147 are cultivated live biotherapeutics, a cell-therapy modality.
|
$153.34M |
$18.77
-3.17%
|
|
Actuate Therapeutics is a biotech company focused on oncology, developing cancer therapies (elraglusib) with clinical-stage programs.
|
$152.84M |
$7.79
-4.06%
|
|
The company focuses on neuropsychiatric drug development for disorders such as MDD, bipolar depression, TRD, and schizophrenia.
|
$152.69M |
$5.64
-6.47%
|
|
Nkarta's lead candidate NKX019 is an allogeneic CAR NK-cell therapy, directly aligning with the Cell Therapy product category.
|
$151.14M |
$2.13
-2.29%
|
|
Direct oncology biotech focus; Cardiff Oncology's lead asset is an oncology drug (onvansertib).
|
$147.02M |
$2.21
-7.14%
|
|
Wound care devices align with first aid and medical product lines.
|
$145.18M |
$38.30
-0.78%
|
|
Avalo directly develops monoclonal antibodies targeting immune dysregulation (e.g., AVTX-9.00), placing the business in Immunology Therapeutics.
|
$145.09M |
$13.40
+3.47%
|
|
Profound's flagship TULSA-PRO system uses MRI for image-guided therapy, placing medical imaging at the core of its product.
|
$144.76M |
$5.87
-10.79%
|
|
Simufilam is an oral small molecule therapeutic being developed as the company's lead drug candidate.
|
$144.44M |
$2.90
-2.84%
|
|
BabySat and Dream Sock function as real-time patient monitoring devices for infants.
|
$142.77M |
$8.64
-5.47%
|
|
NXP900 is an oral small-molecule therapeutic (kinase inhibitor) directly developed by NVCT.
|
$140.86M |
$5.96
-0.33%
|
|
RECELL GO platform and related wound care products are sold as wound care devices/materials, fitting the Wound Care Devices category.
|
$140.50M |
$1.00
|
|
Core product category: ophthalmology devices (surgical laser systems) used for cataract surgery.
|
$140.21M |
$11.89
-1.25%
|
|
Atossa's lead candidate targets metastatic breast cancer, a core oncology focus in biotech/pharma.
|
$139.50M |
$1.08
-7.69%
|
|
Anixa's core focus is oncology-biotech with direct development of cancer therapies, fitting Biotech - Oncology.
|
$139.47M |
$4.33
-12.35%
|
|
Direct product: portable MRI hardware and accompanying imaging software, i.e., medical imaging devices.
|
$136.22M |
$1.75
-13.79%
|
|
RECELL System and its related wound-care products (RECELL GO, RECELL GO mini, Cohealyx, PermeaDerm) are direct medical devices for wound care, fitting the Wound Care Devices category.
|
$135.87M |
$5.14
-6.72%
|
|
Direct focus on rare disease therapies under the Biotech - Rare Diseases category (govorestat and related ARI programs).
|
$133.12M |
$0.94
-9.59%
|
|
Tevogen's core offering is off-the-shelf, precision T cell therapies using the ExacTcell platform, i.e., cell therapy products.
|
$131.50M |
$0.72
-3.36%
|
|
OA pain management and cartilage/tendon repair products are orthopedic device offerings.
|
$131.49M |
$9.12
-1.51%
|
|
Nimacimab is a monoclonal antibody therapeutic targeting CB1 for obesity, representing Skye's core product.
|
$127.35M |
$3.96
-3.77%
|
|
Direct product category: bispecific antibodies (PD-L1xVEGF) developed/distributed by the company.
|
$126.15M |
$19.23
-8.43%
|
|
Company focuses on oncology DARPin therapeutics as a core business line, including lead AML/MDS program (MP0533) and RDTs.
|
$126.14M |
$3.80
+1.06%
|
|
Mobile phlebotomy and on-site laboratory testing services provided to patients.
|
$125.86M |
$1.27
-1.55%
|
|
Provides ODM/contract manufacturing services for nicotine vaping devices from its Malaysia facility.
|
$125.72M |
$2.20
-7.95%
|
|
Company is advancing TCR-T cell therapies, a form of cell therapy for cancer.
|
$125.07M |
$2.21
+0.45%
|
|
EsoCheck is a diagnostic collection device and falls under Diagnostic Equipment.
|
$124.42M |
$1.15
-6.50%
|
|
Cabaletta's lead product rese-cel is a CD19-directed CAR T cell therapy, i.e., a cell therapy product in biotech.
|
$123.81M |
$2.44
-1.61%
|
|
AVIM therapy and Virtue SAB are cardiovascular medical devices developed by OBIO, thus Cardiology Devices.
|
$120.68M |
$3.15
+8.25%
|
|
EB613 and other pipeline candidates are peptide therapeutics administered orally, fitting the Peptide Therapeutics category.
|
$120.45M |
$2.65
+6.00%
|
|
IKT-001Pro is an oral small-molecule prodrug therapy (Imatinib derivative) being developed for PAH.
|
$120.43M |
$1.62
|
|
Surrozen' core ophthalmology-focused ophthalmic drug programs (SZN-8141/8143/113) target retinal diseases and corneal conditions.
|
$117.88M |
$13.77
-1.10%
|
|
Core focus on neuropsychiatric drug development using a non-systemic intranasal pherine platform for CNS disorders (e.g., fasedienol for SAD).
|
$117.51M |
$4.03
-4.73%
|
|
Core business pivot to an AAV-based gene therapy platform with lead programs for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$116.94M |
$1.96
-2.97%
|
|
SERA provides laboratory testing services for PreTRM and related advisory content.
|
$116.41M |
$2.95
-4.22%
|
|
Lead asset azenosertib is an oncology-focused small molecule targeting WEE1, aligning with Biotech - Oncology.
|
$115.84M |
$1.59
-0.93%
|
|
Direct product: tebipenem HBr is an oral small-molecule therapeutic for complicated urinary tract infections, representing Spero Therapeutics' core asset.
|
$114.62M |
$2.05
+1.99%
|
|
Armata develops bacteriophage-based therapeutics for bacterial infections, aligning with Immunology Therapeutics.
|
$112.92M |
$3.12
+0.65%
|
|
Directly develops a gene therapy product (Ixo-vec) for an ocular indication, using AAV-based delivery.
|
$112.60M |
$5.39
+0.09%
|
|
Direct Alzheimer's disease therapeutics product line (ZUNVEYL) targets mild-to-moderate Alzheimer's disease.
|
$112.46M |
$7.02
-7.99%
|
|
LIBERTY Endovascular Robotic Surgical System is a surgical device delivering robotic assistance in endovascular procedures.
|
$111.68M |
$3.07
-3.15%
|
|
IMDX develops and sells ddPCR-based diagnostic tests/kits (GraftAssure family) used for organ transplant monitoring.
|
$111.25M |
$3.89
+2.37%
|
|
Development of a GMP-compliant manufacturing factory through Nika Europe signals in-house pharmaceutical production capacity, consistent with contract manufacturing capabilities.
|
$109.82M |
$0.32
|
|
NNBR produces machined titanium forgings and components used in orthopedic implants (hip replacements), aligning with Orthopedic Devices.
|
$109.47M |
$2.17
-0.91%
|
|
SL-325 is a high-affinity monoclonal antibody targeting DR3, representing the core antibody therapeutic lead.
|
$109.21M |
$2.28
+1.33%
|
|
Agenus' core oncology program centers on botensilimab (BOT) and balstilimab (BAL), a differentiated immuno-oncology therapy portfolio.
|
$108.84M |
$3.97
-6.81%
|
|
Pro-Dex manufactures autoclavable, battery-powered and electric surgical drivers and shavers, which falls under Surgical Equipment.
|
$108.69M |
$33.33
-4.35%
|
|
SGT-610 targets Gorlin Syndrome, a rare genetic disease, aligning with the Biotech - Rare Diseases theme.
|
$108.62M |
$38.99
-2.48%
|
|
The tau proteoform assay and proteomics platform can function as diagnostic‑equipment style offerings in research/clinical contexts.
|
$107.30M |
$0.85
-6.53%
|
|
MGX is developing a gene therapy/gene editing platform (metagenomics-derived toolbox) with in vivo and ex vivo capabilities.
|
$106.91M |
$2.86
-8.04%
|
|
Achieve Life Sciences' direct product is cytisinicline, an oral small-molecule therapeutic for nicotine dependence, which corresponds to the 'Oral Small Molecule Therapeutics' investable theme.
|
$106.83M |
$3.08
-7.23%
|
|
Core focus on antibody-based oncology therapeutics (bispecifics and ADCs) directly aligns with Biotech - Oncology.
|
$106.62M |
$1.69
-4.52%
|
|
Medical devices & biometrics context via X5 medical care products and wearables power.
|
$106.62M |
$6.41
-6.01%
|
|
Etripamil is a cardiovascular drug (calcium channel blocker) aimed at PSVT and AFib-RVR, making Cardiovascular Drugs the core product category.
|
$106.39M |
$1.99
-5.24%
|
|
NCSM provides tracer diagnostics hardware/solutions, corresponding to Diagnostic Equipment.
|
$106.18M |
$41.79
-4.41%
|
|
Product is used for medical imaging in radiology (breast health screening) and is FDA-cleared as a software-based medical device.
|
$105.91M |
$3.87
|
|
HilleVax is a vaccine-focused biotech developing norovirus vaccines (HIL-214.00 and HIL-216.00), directly aligning with the Vaccines tag.
|
$104.79M |
$2.09
|
|
Lead asset sabirnetug is a monoclonal antibody therapeutic targeting soluble AßOs in Alzheimer's disease; qualifies as Monoclonal Antibody Therapeutics.
|
$104.79M |
$1.73
-3.35%
|
|
Patient monitoring functionality via therapy devices and adherence data.
|
$103.85M |
$2.41
-4.37%
|
|
ELYXYB (celecoxib oral solution) and GLOPERBA (colchicine oral solution) are oral small-molecule therapeutics directly produced and marketed by Scilex.
|
$103.79M |
$14.93
-15.27%
|
|
Upright MRI scanners are diagnostic equipment; FONAR manufactures and sells this equipment.
|
$102.87M |
$15.62
-0.27%
|
|
EUDA is pivoting to stem-cell and regenerative medicine, including iPSC-based cell therapies, making Cell Therapy a core current product/technology focus.
|
$102.23M |
$2.86
+4.38%
|
|
COYA's autologous Treg cell therapy program (COYA 101) and exosome-based strategies place it in the cell therapy space.
|
$101.52M |
$6.07
-3.04%
|
|
FB102 is a therapeutic monoclonal antibody targeting CD122 for autoimmune diseases, representing Forte Biosciences' core immunology-focused drug development program.
|
$100.53M |
$15.27
+0.79%
|
|
ALXO's lead and preclinical programs include antibody-drug conjugates (ADC), notably ALX2004 and evorpacept-based combos.
|
$99.94M |
$1.76
-5.88%
|
|
XTNT's core products are orthopedic devices, including spinal implants.
|
$99.70M |
$0.72
-3.30%
|
|
Lead asset CBP-201 is a monoclonal antibody targeting IL-4Rα, placing CNTB's direct product category in Monoclonal Antibody Therapeutics.
|
$98.90M |
$1.74
-17.77%
|
|
Oramed's primary business is developing and commercializing pharmaceutical/biotech therapies with a focus on oral protein delivery (ORMD-0801 for insulin), aligning with the Large Cap Pharma / Pharmaceuticals & Biotechnology investable theme.
|
$98.45M |
$2.41
+1.26%
|
|
Lead product candidate is a small molecule therapeutic (selonabant) and the company developing oral small molecule therapeutics, with a strategic IV formulation for pediatric cannabis toxicity.
|
$95.32M |
$2.32
+2.20%
|
|
Efzofitimod is an immunomodulatory biologic addressing inflammation and fibrosis, placing ATYR in Immunology Therapeutics.
|
$94.34M |
$1.06
-0.93%
|
|
INOVIO's core DNA Medicines platform and SynCon/CELLECTRA approach represent its primary gene therapy technology for delivering therapeutic proteins in vivo.
|
$94.25M |
$2.57
-1.91%
|
|
Atara's lead program tab-cel (Ebvallo) is a allogeneic cell therapy, i.e., a cell-based immunotherapy.
|
$93.18M |
$15.09
-3.45%
|
|
Pelareorep is a cancer-focused oncolytic virus immunotherapy, which directly constitutes the company's core oncology product.
|
$92.49M |
$1.20
-5.51%
|
|
The platform supports patient monitoring and remote care workflows.
|
$92.01M |
$5.82
-5.98%
|
|
PLRX's PLN-101095 is an oncology program targeting ICI-refractory solid tumors, making Biotech - Oncology a core segment.
|
$91.47M |
$1.49
-2.61%
|
|
Direct focus on oncology; Champions Oncology specializes in oncology translational research and PDX-based models.
|
$90.10M |
$6.54
-0.46%
|
|
Develops monoclonal antibody therapeutics (SAFEbody/POWERbody platforms) for cancer.
|
$86.33M |
$1.95
-1.52%
|
|
Burning Rock Biotech operates in oncology biotechnology with MRD and MCED testing, a core oncology diagnostics business.
|
$86.30M |
$8.36
-4.46%
|
|
Immunic's pipeline consists of oral small-molecule therapeutics (IMU-838 and IMU-856) targeting immunology/autoimmune diseases, representing the core product category.
|
$86.09M |
$0.90
-2.61%
|
|
ATH434 is a small-molecule therapeutic candidate (likely oral) targeting neurodegenerative pathways, representing Alterity's core product.
|
$85.62M |
$0.01
|
|
Pocono Pharmaceuticals' contract manufacturing capabilities, including production of topical/transdermal products, fit the Contract Manufacturing Organization (CMO) category.
|
$83.77M |
$7.51
-4.21%
|
|
Directly developing and marketing an oral small-molecule therapeutic (zervimesine/CT1812) for neurodegenerative diseases, fitting the 'Oral Small Molecule Therapeutics' category.
|
$83.69M |
$1.35
+1.50%
|
|
Healthcare-focused high-value applications, biometrics, and patient-safety integrations align with Medical Devices & Biometrics.
|
$83.37M |
$3.53
-7.11%
|
Showing page 7 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
